| Year |
Title |
Altmetric |
| 2023
|
Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.
Australian and New Zealand Journal of Psychiatry.
57:93-103.
2023
|
|
| 2023
|
Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department.
Pediatric Emergency Care.
39:6-12.
2023
|
|
| 2022
|
The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder.
Journal of Affective Disorders.
315:13-16.
2022
|
|
| 2022
|
Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder.
Acta Psychiatrica Scandinavica.
145:615-627.
2022
|
|
| 2022
|
Initial Severity and Depressive Relapse in Cognitive Behavioral Therapy and Antidepressant Medications: An Individual Patient Data Meta-analysis.
Cognitive Therapy and Research.
46:517-531.
2022
|
|
| 2022
|
SIBAT—A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.
Innovations in clinical neuroscience.
19:36-47.
2022
|
|
| 2022
|
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.
Molecular Psychiatry.
27:1286-1299.
2022
|
|
| 2022
|
Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response.
Journal of Affective Disorders.
300:41-49.
2022
|
|
| 2022
|
Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.
Psychiatry Research.
308.
2022
|
|
| 2022
|
Treatment Response to Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior Without Evidence of Early Response: A Pooled Post Hoc Analysis of ASPIRE
2022
|
|
| 2021
|
Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response.
Psychiatry Research.
305.
2021
|
|
| 2021
|
A Pilot Study of Nicotine Replacement Therapy Sampling and Selection to Increase Medication Adherence in Low-Income Smokers.
Nicotine and Tobacco Research.
23:1575-1583.
2021
|
|
| 2021
|
Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.
Journal of Psychiatric Research.
140:205-213.
2021
|
|
| 2021
|
Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial
2021
|
|
| 2021
|
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials.
Depression and Anxiety.
38:114-123.
2021
|
|
| 2021
|
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.
Psychiatry Research.
296.
2021
|
|
| 2021
|
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.
Annals of Clinical Psychiatry.
33:18-26.
2021
|
|
| 2021
|
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
Journal of Clinical Psychiatry.
82.
2021
|
|
| 2021
|
Obesogenic medications and weight gain over 24 weeks in patients with depression: Results from the GUIDED study.
Psychopharmacology bulletin.
51:8-30.
2021
|
|
| 2020
|
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Journal of Affective Disorders.
277:478-485.
2020
|
|
| 2020
|
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
International Clinical Psychopharmacology.
35:313-321.
2020
|
|
| 2020
|
Development of a patient decision aid for treatment resistant depression.
Journal of Affective Disorders.
275:299-306.
2020
|
|
| 2020
|
Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
American Journal of Geriatric Psychiatry.
28:933-945.
2020
|
|
| 2020
|
Naloxone Training From Nonmedical Personnel: Benefits Before, During, and After Overdose Events.
Journal of Addiction Medicine.
14:e220-e225.
2020
|
|
| 2020
|
Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
Psychiatry Research.
290.
2020
|
|
| 2020
|
Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response.
Journal of Affective Disorders.
273:131-137.
2020
|
|
| 2020
|
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
Depression and Anxiety.
37:485-495.
2020
|
|
| 2020
|
150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression
2020
|
|
| 2020
|
180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin
2020
|
|
| 2020
|
181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder
2020
|
|
| 2020
|
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
Journal of Affective Disorders.
266:772-781.
2020
|
|
| 2020
|
Erratum: Prevention of recurrence after recovery from a major depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: phase 2 of a 2-phase randomized clinical trial (JAMA Psychiatry (2019) DOI: 10.1001/jamapsychiatry.2019.3900).
JAMA Psychiatry.
77:328.
2020
|
|
| 2020
|
Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial.
Depression and Anxiety.
37:224-233.
2020
|
|
| 2020
|
Prevention of Recurrence after Recovery from a Major Depressive Episode with Antidepressant Medication Alone or in Combination with Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial.
JAMA Psychiatry.
77:237-245.
2020
|
|
| 2020
|
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: A case report.
Annals of General Psychiatry.
19.
2020
|
|
| 2020
|
Effect of race on the relationship between child maltreatment and obesity in Whites and Blacks
2020
|
|
| 2019
|
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.
BMC Psychiatry.
19.
2019
|
|
| 2019
|
Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship.
Journal of Affective Disorders.
259:164-172.
2019
|
|
| 2019
|
Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression
2019
|
|
| 2019
|
Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors.
Journal of Affective Disorders.
257:17-22.
2019
|
|
| 2019
|
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Genetics in Medicine.
21:2255-2263.
2019
|
|
| 2019
|
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial.
JAMA Psychiatry.
76:893-903.
2019
|
|
| 2019
|
Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies.
Journal of Psychiatric Research.
114:211-213.
2019
|
|
| 2019
|
Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study.
American Journal of Psychiatry.
176:428-438.
2019
|
|
| 2019
|
Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder
2019
|
|
| 2019
|
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
Journal of Psychiatric Research.
111:59-67.
2019
|
|
| 2019
|
Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale.
Journal of Affective Disorders.
246:126-131.
2019
|
|
| 2019
|
49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial
2019
|
|
| 2019
|
A phase 2, randomized, double-blind, placebo-controlled ST of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY).
Journal of Clinical Psychiatry.
80.
2019
|
|
| 2019
|
Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials.
Acta Neuropsychiatrica.
2019
|
|
| 2019
|
Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial.
Journal of Clinical Psychiatry.
80.
2019
|
|
| 2019
|
Serotonin and Norepinephrine Reuptake Inhibitors.
Handbook of experimental pharmacology.
250:145-180.
2019
|
|
| 2018
|
Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder.
Acta Neuropsychiatrica.
30:297-305.
2018
|
|
| 2018
|
Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression.
Australian and New Zealand Journal of Psychiatry.
52:994-1002.
2018
|
|
| 2018
|
Treatment outcomes of acute bipolar depressive episode with psychosis.
Depression and Anxiety.
35:402-410.
2018
|
|
| 2018
|
Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation.
Psychopharmacology bulletin.
48:22-28.
2018
|
|
| 2018
|
Role of complex epigenetic switching in tumor necrosis factor-α upregulation in the prefrontal cortex of suicide subjects.
American Journal of Psychiatry.
175:262-274.
2018
|
|
| 2018
|
Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial.
JAMA Psychiatry.
75:139-148.
2018
|
|
| 2018
|
Corrigendum to bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183–189], (S0165032716323047), (10.1016/j.jad.2017.03.070)).
Journal of Affective Disorders.
225:775-777.
2018
|
|
| 2018
|
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).
Brain Stimulation.
11:75-84.
2018
|
|
| 2018
|
Efficacy of ziprasidone augmentation of escitalopram for cognitive symptoms of major depressive disorder.
Journal of Clinical Psychiatry.
79:55-59.
2018
|
|
| 2018
|
Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: A systematic review and meta-analysis.
Journal of Affective Disorders.
225:422-428.
2018
|
|
| 2018
|
Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial.
Journal of Affective Disorders.
225:563-568.
2018
|
|
| 2017
|
Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder- A systematic review of the magnetic resonance neuroimaging literature.
npj Schizophrenia.
3.
2017
|
|
| 2017
|
Poor quality of life and functioning in bipolar disorder.
International Journal of Bipolar Disorders.
5.
2017
|
|
| 2017
|
Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder.
Journal of Affective Disorders.
223:146-152.
2017
|
|
| 2017
|
Gender-specific relationship between obesity and major depression.
Frontiers in Endocrinology.
8.
2017
|
|
| 2017
|
Response to: Commentary: Sex differences in the peripheral immune system in patients with depression.
Frontiers in Psychiatry.
8.
2017
|
|
| 2017
|
Clinical and genetic predictors of delayed remission after multiple levels of antidepressant treatment: Toward early identification of depressed individuals for advanced care options.
Journal of Clinical Psychiatry.
78:e1291-e1298.
2017
|
|
| 2017
|
Bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study.
Journal of Affective Disorders.
217:183-189.
2017
|
|
| 2017
|
Clinical correlates of acute bipolar depressive episode with psychosis.
Journal of Affective Disorders.
217:29-33.
2017
|
|
| 2017
|
Willingness of Mentally Ill Individuals to Sign Up for a Novel Proposal to Prevent Firearm Suicide.
Suicide and Life-Threatening Behavior.
47:483-492.
2017
|
|
| 2017
|
Sex differences in the peripheral immune system in patients with depression.
Frontiers in Psychiatry.
8.
2017
|
|
| 2017
|
DNA methylation and expression of stress related genes in PBMC of MDD patients with and without serious suicidal ideation.
Journal of Psychiatric Research.
89:115-124.
2017
|
|
| 2017
|
A pilot trial of In vivo NRT sampling to increase medication adherence in community corrections smokers.
Addictive Behaviors.
67:92-99.
2017
|
|
| 2017
|
White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder.
Australian and New Zealand Journal of Psychiatry.
51:355-365.
2017
|
|
| 2017
|
Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study.
Journal of Clinical Psychiatry.
78:449-455.
2017
|
|
| 2017
|
Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder.
Neuropsychopharmacology.
42:864-875.
2017
|
|
| 2017
|
Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder.
Depression and Anxiety.
34:281-290.
2017
|
|
| 2016
|
Depression, Antidepressants, and Weight Gain in Children.
Obesity.
24:2450.
2016
|
|
| 2016
|
Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine—A clinical study.
Asian Journal of Psychiatry.
24:17-22.
2016
|
|
| 2016
|
Psilocybin and palliative end-of-life care.
Journal of Psychopharmacology.
30:1207-1208.
2016
|
|
| 2016
|
Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study.
Journal of Affective Disorders.
205:159-164.
2016
|
|
| 2016
|
Ziprasidone augmentation for anxious depression.
International Clinical Psychopharmacology.
31:341-346.
2016
|
|
| 2016
|
A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression.
American Journal of Psychiatry.
173:816-826.
2016
|
|
| 2016
|
Specific pharmacological effects of paroxetine comprise psychological but not somatic symptoms of depression.
PLoS One.
11.
2016
|
|
| 2016
|
Notice of Retraction and Replacement. Hollon et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2014;71(10):1157-1164.
JAMA Psychiatry.
73:639-640.
2016
|
|
| 2016
|
An altered peripheral IL6 response in major depressive disorder.
Neurobiology of Disease.
89:46-54.
2016
|
|
| 2016
|
Are placebo-controlled trials of depression safe?.
Lancet Psychiatry.
3:393-395.
2016
|
|
| 2016
|
Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled Acute Study.
Journal of Clinical Psychiatry.
77:654-660.
2016
|
|
| 2016
|
Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity..
Journal of Diabetes and Metabolism.
7.
2016
|
|
| 2016
|
The course of illness after initial diagnosis of major depression.
JAMA Psychiatry.
73:321-322.
2016
|
|
| 2016
|
A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report.
Journal of Affective Disorders.
192:212-218.
2016
|
|
| 2016
|
Molecular analyses of circadian gene variants reveal sex-dependent links between depression and clocks.
Translational Psychiatry.
6.
2016
|
|
| 2016
|
A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder..
Therapeutic Advances in Psychopharmacology.
6:4-12.
2016
|
|
| 2016
|
Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.
Acta Psychiatrica Scandinavica.
133:144-153.
2016
|
|
| 2016
|
Baseline disability and poor functioning in Bipolar disorder predict worse outcomes: Results from the Bipolar CHOICE study.
Journal of Clinical Psychiatry.
77:100-108.
2016
|
|
| 2016
|
Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): A pragmatic 6-month trial of lithium versus quetiapine for Bipolar disorder.
Journal of Clinical Psychiatry.
77:90-99.
2016
|
|
| 2015
|
Association of obesity and inflammatory marker levels on treatment outcome: Results from a double-blind, randomized study of adjunctive l-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
Journal of Clinical Psychiatry.
76:1635-1641.
2015
|
|
| 2015
|
Ziprasidone augmentation of escitalopram for major depressive disorder: Efficacy results from a randomized, Double-Blind, Placebo-Controlled Study.
American Journal of Psychiatry.
172:1251-1258.
2015
|
|
| 2015
|
The pro-inflammatory profile of depressed patients is (partly) related to obesity.
Journal of Psychiatric Research.
70:91-97.
2015
|
|
| 2015
|
Assessment of the Efficacy and Safety of BMS-820836 in Patients with Treatment-Resistant Major Depression: Results from 2 Randomized, Double-Blind Studies.
Journal of Clinical Psychopharmacology.
35:454-459.
2015
|
|
| 2015
|
Childhood maltreatment increases the risk for visceral obesity.
Obesity.
23:1625-1632.
2015
|
|
| 2015
|
Reply to commentary by rothschild: "A blood test for depression?".
Journal of Clinical Psychiatry.
76:e1038.
2015
|
|
| 2015
|
Psychotherapy use in bipolar disorder: Association with functioning and illness severity.
Australian and New Zealand Journal of Psychiatry.
49:453-461.
2015
|
|
| 2015
|
Gains in employment status following antidepressant medication or cognitive therapy for depression.
British Journal of Psychiatry.
206:332-338.
2015
|
|
| 2015
|
What are the comparative benefits and harms of augmentation treatments in major depression?.
Journal of Clinical Psychiatry.
76:e531-e533.
2015
|
|
| 2015
|
Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE)
2015
|
|
| 2015
|
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar i or II disorder results from the bipolar CHOICE study.
Journal of Clinical Psychopharmacology.
35:68-74.
2015
|
|
| 2015
|
Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression.
Biological Psychiatry.
77:256-265.
2015
|
|
| 2015
|
MDDScore: Confirmation of a blood test to aid in the diagnosis of major depressive disorder.
Journal of Clinical Psychiatry.
76:e199-e206.
2015
|
|
| 2015
|
Rapid Follow-Up for Patients After Psychiatric Crisis.
Community Mental Health Journal.
51:139-144.
2015
|
|
| 2015
|
Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors.
Translational Psychiatry.
5.
2015
|
|
| 2014
|
Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder a randomized clinical trial.
JAMA Psychiatry.
71:1157-1164.
2014
|
|
| 2014
|
Erratum: "Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar i or II disorder: Results from the bipolar CHOICE trial" [Journal of Affective Disorders (2014) 161 (30-35)].
Journal of Affective Disorders.
167:259-260.
2014
|
|
| 2014
|
Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer: In regard to Kirchheiner et al
2014
|
|
| 2014
|
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar i or II disorder: Results from the Bipolar CHOICE trial.
Journal of Affective Disorders.
161:30-35.
2014
|
|
| 2014
|
Antidepressants and suicide attempts in children.
Pediatrics.
133:204-210.
2014
|
|
| 2014
|
Clinical and health outcomes initiative in comparative effectiveness for bipolar disorder (Bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder.
Clinical Trials.
11:114-127.
2014
|
|
| 2014
|
The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: An interrupted time series study of 228,876 pregnancies.
Archives of Women's Mental Health.
17:17-26.
2014
|
|
| 2014
|
Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts.
Experimental Cell Research.
320:343-353.
2014
|
|
| 2014
|
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Progress in Neuro-Psychopharmacology and Biological Psychiatry.
48:86-91.
2014
|
|
| 2014
|
Early life trauma and directional brain connectivity within major depression.
Human Brain Mapping.
35:4815-4826.
2014
|
|
| 2013
|
Reliability and validity of the Symptoms of Depression Questionnaire (SDQ)
2013
|
|
| 2013
|
Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder.
Journal of Affective Disorders.
151:722-727.
2013
|
|
| 2013
|
Assessing effects of L-methylfolate in depression management: Results of a real-world patient experience trial.
The primary care companion for CNS disorders.
15.
2013
|
|
| 2013
|
Identifying suicidal behavior among adolescents using administrative claims data.
Pharmacoepidemiology and Drug Safety.
22:769-775.
2013
|
|
| 2013
|
Increasing use of atypical antipsychotics and anticonvulsants during pregnancy.
Pharmacoepidemiology and Drug Safety.
22:794-801.
2013
|
|
| 2013
|
Treatment resistant depression: Strategies for primary care topical collection on psychiatry in primary care.
Current Psychiatry Reports.
15.
2013
|
|
| 2013
|
Erratum: Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies (American Journal of Obstetrics and Gynecology (2012) 207 49 (e1-9)).
American Journal of Obstetrics and Gynecology.
208:326.
2013
|
|
| 2013
|
Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: A Pilot and Replication Study.
Molecular Psychiatry.
18:332-339.
2013
|
|
| 2013
|
Convergence and divergence in the delivery of cognitive therapy intwo randomized clinical trials.
Behaviour Research and Therapy.
51:493-498.
2013
|
|
| 2013
|
Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.
Behaviour Research and Therapy.
51:392-398.
2013
|
|
| 2013
|
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development.
Australian and New Zealand Journal of Psychiatry.
47:26-42.
2013
|
|
| 2012
|
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind,,parallel-sequential trials.
American Journal of Psychiatry.
169:1267-1274.
2012
|
|
| 2012
|
Does concomitant use of NSAIDs reduce the effectiveness of antidepressants?.
American Journal of Psychiatry.
169:1012-1015.
2012
|
|
| 2012
|
Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: The role of therapist adherence and the therapeutic alliance.
Journal of Consulting and Clinical Psychology.
80:373-381.
2012
|
|
| 2012
|
Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene
2012
|
|
| 2012
|
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
Journal of Clinical Psychiatry.
73:1541-1547.
2012
|
|
| 2012
|
Effort-based decision-making in major depressive disorder: A translational model of motivational anhedonia.
Journal of Abnormal Psychology.
121:553-558.
2012
|
|
| 2012
|
Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies.
American Journal of Obstetrics and Gynecology.
207:49.e1-49.e9.
2012
|
|
| 2012
|
Oxidative stress and glutathione response in tissue cultures from persons with major depression.
Journal of Psychiatric Research.
46:1326-1332.
2012
|
|
| 2012
|
Review of pharmacological treatment in mood disorders and future directions for drug development.
Neuropsychopharmacology.
37:77-101.
2012
|
|
| 2011
|
A Randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.
Clinical Neuropharmacology.
34:224-233.
2011
|
|
| 2011
|
Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology.
Neuropsychopharmacology.
36:2375-2394.
2011
|
|
| 2011
|
Inflammation in depression: Is adiposity a cause?.
Dialogues in Clinical Neuroscience.
13:41-54.
2011
|
|
| 2011
|
Agomelatine for the treatment of major depressive disorder.
Expert Opinion on Pharmacotherapy.
12:2411-2419.
2011
|
|
| 2011
|
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report.
Journal of Affective Disorders.
133:467-476.
2011
|
|
| 2011
|
Sustained amygdala response to both novel and newly familiar faces characterizes inhibited temperament.
Social Cognitive and Affective Neuroscience.
6:621-629.
2011
|
|
| 2011
|
Suicidal behavior differs among early and late adolescents treated with antidepressant agents.
Pediatrics.
128:447-454.
2011
|
|
| 2011
|
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: A randomized, open comparison in outpatients with bipolar depression.
Annals of Clinical Psychiatry.
23:193-201.
2011
|
|
| 2011
|
Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression.
Molecular Psychiatry.
16:751-762.
2011
|
|
| 2011
|
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study.
American Journal of Psychiatry.
168:689-701.
2011
|
|
| 2011
|
Two aspects of the therapeutic alliance: Differential relations with depressive symptom change.
Journal of Consulting and Clinical Psychology.
79:279-283.
2011
|
|
| 2011
|
Challenges and algorithm-guided treatment in major depressive disorder..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2011
|
Crisis of confidence: antidepressant risk versus benefit..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2011
|
The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.
Journal of Clinical Psychopharmacology.
31:31-38.
2011
|
|
| 2011
|
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Journal of Clinical Psychiatry.
72:1405-1412.
2011
|
|
| 2011
|
Childhood trauma history differentiates amygdala response to sad faces within MDD.
Journal of Psychiatric Research.
45:886-895.
2011
|
|
| 2011
|
Evidence for the use of l-methylfolate combined with antidepressants in MDD..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2011
|
Moderators of antidepressant response in major depression..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2011
|
Performance improvement CME: algorithms and EMRs in depression..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2011
|
The current crisis of confidence in antidepressants.
Journal of Clinical Psychiatry.
72:27-33.
2011
|
|
| 2011
|
Using algorithms and computerized decision support systems to treat major depression..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2011
|
Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression..
Journal of Clinical Psychiatry.
72.
2011
|
|
| 2010
|
Biological activities of 7-dehydrocholesterol-derived oxysterols: Implications for Smith-Lemli-Opitz syndrome.
Journal of Lipid Research.
51:3259-3269.
2010
|
|
| 2010
|
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
Journal of Affective Disorders.
126:420-429.
2010
|
|
| 2010
|
Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder
2010
|
|
| 2010
|
Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression.
Psychological Medicine.
40:1379-1387.
2010
|
|
| 2010
|
Efficacy, safety and tolerability of Symbyax® for acute-phase management of treatment-resistant depression
2010
|
|
| 2010
|
Depressive realism and clinical depression.
Behaviour Research and Therapy.
48:257-265.
2010
|
|
| 2010
|
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: Results of an 8-week open label trial
2010
|
|
| 2010
|
Therapeutic options for treatment-resistant depression.
CNS Drugs.
24:131-161.
2010
|
|
| 2010
|
Antidepressant drug effects and depression severity: A patient-level meta-analysis.
Journal of the American Medical Association.
303:47-53.
2010
|
|
| 2010
|
Acute bipolar depression: A review of the use of olanzapine/fluoxetine
2010
|
|
| 2010
|
Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data.
American Journal of Health-System Pharmacy.
67:27-37.
2010
|
|
| 2010
|
Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression.
Progress in Neurobiology.
91:275-299.
2010
|
|
| 2009
|
St John's wort (Hypericum perforatum) in major depression.
Journal of Clinical Psychiatry.
70:23-27.
2009
|
|
| 2009
|
Long-term management of depression: Tips for adjusting the treatment plan as the patient's needs change.
Journal of Clinical Psychiatry.
70:32-37.
2009
|
|
| 2009
|
Amygdala temporal dynamics: Temperamental differences in the timing of amygdala response to familiar and novel faces.
BMC Neuroscience.
10.
2009
|
|
| 2009
|
Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder.
Australian and New Zealand Journal of Psychiatry.
43:956-967.
2009
|
|
| 2009
|
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
Psychopharmacology bulletin.
42:5-20.
2009
|
|
| 2009
|
Personality change during depression treatment: A placebo-controlled trial.
JAMA Psychiatry.
66:1322-1330.
2009
|
|
| 2009
|
Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls.
International Journal of Neuropsychopharmacology.
12:1223-1232.
2009
|
|
| 2009
|
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: Review of efficacy and safety data.
Expert Opinion on Pharmacotherapy.
10:2145-2159.
2009
|
|
| 2009
|
Prediction of Response to Medication and Cognitive Therapy in the Treatment of Moderate to Severe Depression.
Journal of Consulting and Clinical Psychology.
77:775-787.
2009
|
|
| 2009
|
Symbyax ® (olanzapine and fluoxetine HCl) for the acute treatment of treatment-resistant depression
2009
|
|
| 2009
|
Treatment-resistant depression: Understanding its nature and the burden of care
2009
|
|
| 2009
|
Early adverse events, HPA activity and rostral anterior cingulate volume in MDD.
PLoS One.
4.
2009
|
|
| 2009
|
Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A.
Neuroscience.
158:1406-1415.
2009
|
|
| 2009
|
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
Journal of Psychiatric Research.
43:247-254.
2009
|
|
| 2009
|
Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report
2009
|
|
| 2009
|
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues.
Neuropsychiatric Disease and Treatment.
5:369-383.
2009
|
|
| 2009
|
Psychiatric profile and attention deficits in postural tachycardia syndrome.
Journal of Neurology, Neurosurgery and Psychiatry.
80:339-344.
2009
|
|
| 2009
|
The role of L-methylfolate in depressive disorders: commentary.
2009
|
|
| 2009
|
The role of residual symptoms in nonadherence to treatment.
2009
|
|
| 2008
|
Adjunctive use of modafinil in bipolar patients: Just another stimulant or not?.
Current Psychiatry Reports.
10:520-524.
2008
|
|
| 2008
|
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
Current Psychiatry Reports.
10:481-486.
2008
|
|
| 2008
|
Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy.
Journal of Affective Disorders.
110:161-166.
2008
|
|
| 2008
|
Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression.
Genes, Brain and Behavior.
7:487-495.
2008
|
|
| 2008
|
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Acta Psychiatrica Scandinavica.
117:253-259.
2008
|
|
| 2008
|
Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder.
British Journal of Psychiatry.
192:124-129.
2008
|
|
| 2008
|
The history and current state of antidepressant clinical trial design: A call to action for proof-of-concept studies.
Journal of Clinical Psychiatry.
69:1513-1528.
2008
|
|
| 2007
|
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases.
Biological Psychiatry.
62:1371-1379.
2007
|
|
| 2007
|
Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents.
Biological Psychiatry.
62:1217-1227.
2007
|
|
| 2007
|
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
International Clinical Psychopharmacology.
22:348-355.
2007
|
|
| 2007
|
Augmentation strategies to increase antidepressant efficacy.
Journal of Clinical Psychiatry.
68:18-22.
2007
|
|
| 2007
|
The Relation of Patients' Treatment Preferences to Outcome in a Randomized Clinical Trial.
Behavior Therapy.
38:209-217.
2007
|
|
| 2007
|
The neurobiology of treatment-resistant depression
2007
|
|
| 2007
|
Changes in patients' beliefs about the causes of their depression following successful treatment.
Cognitive Therapy and Research.
31:437-449.
2007
|
|
| 2007
|
Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
International Journal of Clinical Practice.
61:1337-1348.
2007
|
|
| 2007
|
Issues related to adherence in the treatment of depression
2007
|
|
| 2007
|
Sudden Gains in Cognitive Therapy of Depression and Depression Relapse/Recurrence.
Journal of Consulting and Clinical Psychology.
75:404-408.
2007
|
|
| 2007
|
Progressive Resistance to a Selective Serotonin Reuptake Inhibitor but Not to Cognitive Therapy in the Treatment of Major Depression.
Journal of Consulting and Clinical Psychology.
75:267-276.
2007
|
|
| 2007
|
Comparison of quality of life measures in a depressed population.
Journal of Nervous and Mental Disease.
195:219-225.
2007
|
|
| 2007
|
The Molecular Neurobiology of Depression.
Psychiatric Clinics of North America.
30:1-11.
2007
|
|
| 2007
|
A randomized, double-blind, crossover trial of modafinil on mood.
Journal of Clinical Psychopharmacology.
27:76-79.
2007
|
|
| 2007
|
Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer
2007
|
|
| 2007
|
Polymorphisms in the Regulatory Region of the Human Serotonin 5-HT2A Receptor Gene (HTR2A) Influence Gene Expression.
Biological Psychiatry.
61:167-173.
2007
|
|
| 2007
|
Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort.
Journal of Clinical Psychiatry.
68:1931-1938.
2007
|
|
| 2007
|
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis.
Journal of Clinical Psychiatry.
68:826-831.
2007
|
|
| 2007
|
Case Studies in Bipolar Depression: Best Practices for the Outpatient
2007
|
|
| 2007
|
Dr. Shelton replies [4].
Journal of Clinical Psychiatry.
68:1619.
2007
|
|
| 2007
|
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study.
Journal of Clinical Psychiatry.
68:1071-1077.
2007
|
|
| 2007
|
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study.
Journal of Clinical Psychiatry.
68:1014-1023.
2007
|
|
| 2007
|
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases.
Journal of Clinical Psychiatry.
68:1246-1256.
2007
|
|
| 2006
|
Praise for a critical perspective.
Behavioral and Brain Sciences.
29:405-405.
2006
|
|
| 2006
|
The return of fixed combinations in psychiatry: Fluoxetine and olanzapine combination.
Therapeutics and Clinical Risk Management.
2:187-192.
2006
|
|
| 2006
|
Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: A randomized comparison of standard- and higher-dosing strategies.
Journal of Clinical Psychopharmacology.
26:250-258.
2006
|
|
| 2006
|
Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research.
Journal of Clinical Psychiatry.
67:27-30.
2006
|
|
| 2006
|
The nature of the discontinuation syndrome associated with antidepressant drugs.
Journal of Clinical Psychiatry.
67:3-7.
2006
|
|
| 2006
|
Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension.
Neuroscience.
139:931-946.
2006
|
|
| 2006
|
Management of major depressive disorder following failure of first antidepressant treatment
2006
|
|
| 2006
|
Presenting characteristics of depressed outpatients as a function of recurrence: Preliminary findings from the STAR*D clinical trial.
Journal of Psychiatric Research.
40:59-69.
2006
|
|
| 2006
|
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
Journal of Clinical Psychiatry.
67:1674-1681.
2006
|
|
| 2006
|
Detection of an mRNA polymorphism by differential display..
Methods in Molecular Biology.
317:279-285.
2006
|
|
| 2006
|
Olanzapine/fluoxetine combination for bipolar depression
2006
|
|
| 2006
|
Use of treatment algorithms for depression.
Journal of Clinical Psychiatry.
67:1458-1465.
2006
|
|
| 2005
|
Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder.
Neuropharmacology.
49:724-736.
2005
|
|
| 2005
|
Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase
2005
|
|
| 2005
|
Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features.
Journal of Affective Disorders.
87:43-55.
2005
|
|
| 2005
|
Cognitive therapy vs medications in the treatment of moderate to severe depression.
JAMA Psychiatry.
62:409-416.
2005
|
|
| 2005
|
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
JAMA Psychiatry.
62:417-422.
2005
|
|
| 2005
|
Signal transduction abnormalities in melancholic depression.
International Journal of Neuropsychopharmacology.
8:5-16.
2005
|
|
| 2005
|
Do venlafaxine XR and paroxetine equally influence negative and positive affect?.
Journal of Affective Disorders.
85:333-339.
2005
|
|
| 2005
|
Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance.
Journal of Clinical Psychiatry.
66:1289-1297.
2005
|
|
| 2005
|
Treatment of depression in adolescents with cognitive behavior therapy and medications: A commentary on the TADS project.
Cognitive and Behavioral Practice.
12:149-155.
2005
|
|
| 2004
|
Risperidone and paroxetine given singly and in combination for bipolar depression.
Journal of Clinical Psychiatry.
65:1715-1719.
2004
|
|
| 2004
|
The dual-action hypothesis: Does pharmacology matter?.
Journal of Clinical Psychiatry.
65:5-10.
2004
|
|
| 2004
|
Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signalling in fibroblasts from melancholic deppresed patients.
Neuropsychopharmacology.
29:2081-2087.
2004
|
|
| 2004
|
The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication.
Journal of Clinical Psychiatry.
65:1114-1119.
2004
|
|
| 2004
|
Early- and late-onset startle modulation in unipolar depression.
Psychophysiology.
41:433-440.
2004
|
|
| 2004
|
Assessing the effects of bupropion SR on mood dimensions of depression.
Journal of Affective Disorders.
78:235-241.
2004
|
|
| 2004
|
Differential Expression of Pentraxin 3 in Fibroblasts from Patients with Major Depression.
Neuropsychopharmacology.
29:126-132.
2004
|
|
| 2003
|
The combination of olanzapine and fluoxetine in mood disorders.
Expert Opinion on Pharmacotherapy.
4:1175-1183.
2003
|
|
| 2003
|
The combination of olanzapine and fluoxetine in mood disorders..
Expert Opinion on Pharmacotherapy.
4:1175-1183.
2003
|
|
| 2003
|
The use of antidepressants in novel combination therapies.
Journal of Clinical Psychiatry.
64:14-18.
2003
|
|
| 2003
|
Treating bipolar depression
2003
|
|
| 2002
|
St John's wort for the treatment of depression.
Lancet Neurology.
1:275.
2002
|
|
| 2002
|
Noradrenergic antidepressants: Does chronic treatment increase or decrease nuclear CREB-P?.
Journal of Neural Transmission.
109:91-99.
2002
|
|
| 2002
|
Mechanism of action of antidepressants..
Psychopharmacology bulletin.
36 Suppl 2:123-132.
2002
|
|
| 2001
|
St John's wort was no better than placebo for reducing depression scores.
BMJ Evidence Based Medicine.
6:185.
2001
|
|
| 2001
|
Antidepressant therapy: New targets for drug development.
Expert Opinion on Therapeutic Patents.
11:1693-1711.
2001
|
|
| 2001
|
Can recovery from depression be achieved?.
Psychiatric Services.
52:1469-1478.
2001
|
|
| 2001
|
Detection of an mRNA polymorphism by Differential Display.
Molecular Biotechnology.
19:121-124.
2001
|
|
| 2001
|
Cross-talk between PKA and PKC in human fibroblasts: What are the pharmacotherapeutic implications?.
Journal of Affective Disorders.
65:275-279.
2001
|
|
| 2001
|
Mechanisms of action in the treatment of anxiety.
Journal of Clinical Psychiatry.
62:10-15.
2001
|
|
| 2001
|
St John's wort and major depression [1].
Journal of the American Medical Association.
286:42-45.
2001
|
|
| 2001
|
St john's wort and major depression..
Journal of the American Medical Association.
286.
2001
|
|
| 2001
|
Effectiveness of St John's wort in major depression: A randomized controlled trial.
Journal of the American Medical Association.
285:1978-1986.
2001
|
|
| 2001
|
A novel augmentation strategy for treating resistant major depression.
American Journal of Psychiatry.
158:131-134.
2001
|
|
| 2001
|
Do Dual-Action Neurotransmitter Agents Offer an Advantage in Psychiatric Treatment?
2001
|
|
| 2001
|
Introduction: Remission of anxiety-related disorders.
Journal of Clinical Psychiatry.
62:3-4.
2001
|
|
| 2001
|
Serum thyrotropin concentrations and bioactivity during sleep deprivation in depression.
JAMA Psychiatry.
58:77-83.
2001
|
|
| 2001
|
Steps following attainment of remission: Discontinuation of antidepressant therapy.
The primary care companion for CNS disorders.
3:168-174.
2001
|
|
| 2001
|
Treatment guidelines for major depressive disorder.
Behavior Therapy.
32:235-258.
2001
|
|
| 2000
|
Chronic depression: Now, a treatable condition.
Patient care.
34:56-66.
2000
|
|
| 2000
|
Human fibroblasts as a relevant model to study signal transduction in affective disorders.
Journal of Affective Disorders.
61:51-58.
2000
|
|
| 2000
|
Cellular mechanisms in the vulnerability to depression and response to antidepressants.
Psychiatric Clinics of North America.
23:713-729.
2000
|
|
| 2000
|
Intracellular mechanisms of antidepressant drug action.
Harvard Review of Psychiatry.
8:161-174.
2000
|
|
| 1999
|
The reliability and validity of a measure of self-understanding of interpersonal patterns.
Journal of Counseling Psychology.
46:472-482.
1999
|
|
| 1999
|
Mood-stabilizing drugs in depression.
Journal of Clinical Psychiatry.
60:37-42.
1999
|
|
| 1999
|
Treatment options for refractory depression.
Journal of Clinical Psychiatry.
60:57-63.
1999
|
|
| 1999
|
Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers.
International Journal of Neuropsychopharmacology.
2:187-192.
1999
|
|
| 1998
|
Update on the management of bipolar illness.
Journal of Clinical Psychiatry.
59:484-495.
1998
|
|
| 1997
|
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes.
American Journal of Psychiatry.
154:390-395.
1997
|
|
| 1997
|
The undertreatment of dysthymia.
Journal of Clinical Psychiatry.
58:59-65.
1997
|
|
| 1996
|
cAMP-dependent protein kinase activity in major depression.
American Journal of Psychiatry.
153:1037-1042.
1996
|
|
| 1996
|
β-Adrenoceptor-linked protein kinase A (PKA) activity in human fibroblasts from normal subjects and from patients with major depression.
Neuropsychopharmacology.
15:555-561.
1996
|
|
| 1995
|
Effects of a Safe Person on Induced Distress Following a Biological Challenge in Panic Disorder With Agoraphobia.
Journal of Abnormal Psychology.
104:156-163.
1995
|
|
| 1994
|
The role of sertraline in the management of depression
1994
|
|
| 1993
|
The effects of antidepressants on the thyroid axis in depression.
Biological Psychiatry.
33:120-126.
1993
|
|
| 1993
|
Alprazolam in panic disorder: A retrospective analysis.
Progress in Neuro-Psychopharmacology and Biological Psychiatry.
17:423-434.
1993
|
|
| 1993
|
Cerebrospinal fluid norepinephrine concentrations and dynamics in depressed patients and normal volunteers.
Depression.
1:149-155.
1993
|
|
| 1993
|
Cognitive Therapy for Depression: Conceptual Issues and Clinical Efficacy.
Journal of Consulting and Clinical Psychology.
61:270-275.
1993
|
|
| 1993
|
Pharmacotherapy of panic disorder.
Psychiatric Services.
44:725-726.
1993
|
|
| 1993
|
Sleep deprivation accelerates the response to nortriptyline.
Progress in Neuro-Psychopharmacology and Biological Psychiatry.
17:113-123.
1993
|
|
| 1993
|
The effects of race and comorbidity on clinical diagnosis in patients with psychosis.
Journal of Clinical Psychiatry.
54:96-102.
1993
|
|
| 1992
|
Psychiatric phenomenology in Cushings's disease.
Pharmacopsychiatry.
25:192-198.
1992
|
|
| 1991
|
Biological and psychological aspects of depression.
Behavior Therapy.
22:201-228.
1991
|
|
| 1991
|
Cognitive Therapy and Pharmacotherapy for Depression.
Journal of Consulting and Clinical Psychology.
59:88-99.
1991
|
|
| 1991
|
The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia.
Journal of Neuropsychiatry and Clinical Neurosciences.
3:383-386.
1991
|
|
| 1990
|
Diagnosis and management of panic disorder.
Comprehensive Therapy.
16:11-17.
1990
|
|
| 1988
|
Cerebral structural pathology in schizophrenia: Evidence for a selective prefrontal cortical defect.
American Journal of Psychiatry.
145:154-163.
1988
|
|
| 1987
|
Diltiazem or verapamil prevents haloperidol-induced apomorphine supersensitivity in mice.
Journal of Neural Transmission.
68:241-255.
1987
|
|
| 1987
|
Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY k 8644.
Brain Research.
402:399-402.
1987
|
|
| 1987
|
A relationship between anatomical and physiological brain pathology in schizophrenia: Lateral cerebral ventricular size predicts cortical blood flow.
American Journal of Psychiatry.
144:1277-1282.
1987
|
|
| 1987
|
Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain.
Clinical Neuropharmacology.
10:376-383.
1987
|
|
| 1986
|
A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
Biological Psychiatry.
21:691-694.
1986
|
|
| 1986
|
Consent and liability with neuroleptics: The problem of tardive dyskinesia.
International Journal of Law and Psychiatry.
8:243-252.
1986
|
|
| 1985
|
Metabolism of carbidopa to alphamethyldopamine and alphamethylnorepinephrine in rats.
Biochemical Pharmacology.
34:3623-3626.
1985
|
|
| 1985
|
Nitrendipine-sensitive Ca2+ channels in mouse brain: Evidence for down-regulation of recognition sites after long-term treatment with nifedipine or verapamil
1985
|
|
